SavedAdd your journal

Journals / Glokom Katarakt / 2006 / Cilt: 1 - Sayı: 1

Allergic conjunctivitis and elevated intraocular pressure associated with the use of brimonidine tartrate 0.2%

Topikal brimonidin tartrat %0.2 kullanımına bağlı ortaya çıkan allerjik konjonktivit ve yüksek göz içi basıncı

BANU BOZKURT
Murat İRKEÇ
Pages
67–69
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

When brimonidine was stopped, the IOP was controlled with the combination of topical beta-blocker and carbonic anhydrase inhibitor and the allergic reaction resolved in a month.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We report allergic conjunctivitis and elevated intraocular pressure (IOP) associated with the use of brimonidine tartrate 0.2% in a 68-year-old female patient.
📊
Key Findings & Data:The patient was using brimonidine tartrate 0.2% twice daily for 8 months.
💡
Conclusion & Impact:When brimonidine was stopped, the IOP was controlled with the combination of topical beta-blocker and carbonic anhydrase inhibitor and the allergic reaction resolved in a month.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Göz içi basınç · Glokom · Konjunktivit

Abstract

We report allergic conjunctivitis and elevated intraocular pressure (IOP) associated with the use of brimonidine tartrate 0.2% in a 68-year-old female patient. The patient was using brimonidine tartrate 0.2% twice daily for 8 months. For the last 2 months, she complaint of severe redness, tearing, pain and blurred vision and had been treated with topical antibiotics and steroids with the diagnosis of conjunctivitis and episcleritis. On examination, the conjunctiva was extensively hyperemic and edematous in both eyes and there were multiple giant follicules. The IOP was 35 mmHg in the right eye and 45 mmHg in the left eye. When brimonidine was stopped, the IOP was controlled with the combination of topical beta-blocker and carbonic anhydrase inhibitor and the allergic reaction resolved in a month.

Özet

Topikal brimonidin tartrat %0.2 kullanımına bağlı allerjik konjonktivit ve paradoksik göz içi basıncı (GİB) artışı saptanan 68 yaşında bayan hasta tartışıldı. Sekiz aydır glokom tanısı ile brimonidin tartrat %0.2 kullanan hastanın, son 2 aydır gözlerinde aşırı kızarıklık, sulanma, ağrı ve bulanık görme şikayetleri olduğu ve konjonktivit ve episklerit tanılarıyla topikal antibiyotik ve steroid damla kullandığı öğrenildi. Muayenesinde her iki göz konjonktiva ileri derecede hiperemik ve ödemliydi ve yaygın dev foliküller saptandı. GİB sağda 35 mmHg, solda 45 mmHg olarak ölçüldü. Brimonidin tedavisi kesilerek, topikal beta-blokör, karbonik anhidraz inhibitörü ve rimeksolon tedavisi başlanmasıyla GİB kontrol altına alındı. Allerjik reaksiyon 1 ay içinde tamamen kayboldu.

🔖

Cite This Article

BOZKURT, B., İRKEÇ, M. (2006). Allergic conjunctivitis and elevated intraocular pressure associated with the use of brimonidine tartrate 0.2%. Glokom Katarakt, Cilt: 1 - Sayı: 1, 67–69. https://ajindex.com/articles/226716

References (14)

  1. Walters TR: Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: A review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol 1996;41:19-26
  2. LeBlanc RP, Brimonidine study group 2: Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma and ocular hypertension. Ophthalmology 1998;105:1960-1967
  3. Schuman JS, Horwitz B, Choplin NT, et al.: A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997,115:847-852
  4. Katz U and the Brimonidine Study Group: Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1 -year results in glaucoma patients. Am J Ophthalmol 1999,127:20-26
  5. Ermiş SS, İnan Ü, Oztürk F, ve ark.: Primer açık açılı glokomda %0.2 brimonidinin uzun süreli kullanımının göziçi basıncı ve görme alanına etkisi. Türk Oft. Gaz 2002;32:484-488
  6. Toris CB, Gleason ML, Camras CB: Effects of brimonidine on aqueous humour dynamics in human eyes. Arch Ophthalmol 1995,113:1514-1517
  7. Stewart WC, Garrison PM: B-Blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse effects. Arch Intern Med 1998;158:221-226
  8. Köz ÖG, Yarangümeli A, Kural G: Normotensif glokom olgularinda topikal betaksolol ve brimonidinin kardiyovasküler sistem üzerindeki etkileri. Türk Oft. Gaz 2003;33:183-188
  9. Blondeau P, Rousseau JA: Allergic reactions to brimonidine in patients treated for glaucoma. Can J Ophthalmol 2002;37:21-26
  10. Manni G, Centofanti M, Sacchetti M, ve ark.: Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy. J Glaucoma 2004;13:163-167
  11. Watts P, Hawksworth N: Delayed hypersensitivity to brimonidine tartrate 0.2% associated with high intraocular pressure. Eye 2002,16:132-135
  12. Mushtag B, Sardar J, Matthews TD: A paradoxical ocular effect of brimonidine. Am J Ophthalmol 2003;135:102-103
  13. Osborne SA, Montgomery DM, Morris D, et al.: Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye 2005;19:129-137
  14. Becker HI, Walton RC, Diamant Jl, et al.: Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate. Arch Ophthalmol 2004;l22:1063-1066. 15.